BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pharmaceutical Formulations (PHFR) Announces The Resignation Of Its President And COO


10/19/2005 5:13:04 PM

EDISON, N.J., March 18 /PRNewswire-FirstCall/ -- Pharmaceutical Formulations, Inc. (BULLETIN BOARD: PHFR) ("PFI" or the "Company") announced today that its President and Chief Operating Officer, Mr. Michael Zeher, has submitted his resignation to the Company, in order to pursue other interests. Mr. Zeher has also resigned as a member of the Company's board of directors. Dr. James Ingram, Chairman and Chief Executive Officer of the Company, will assume Mr. Zeher's responsibilities, effective immediately.

"We appreciate Mike's contributions to PFI during his tenure as President," said Dr. Ingram. "We wish him well in his future endeavors."

Dr. Ingram's immediate focus will be the implementation of several cost reduction initiatives, including personnel reductions and warehouse relocation. PFI has also entered into an agreement with Step 3 Consulting, with the objective of improving manufacturing productivity, reducing costs and improving sales margin. This program is ongoing.

An aggressive cost reduction program is necessitated by the very soft sales environment that PFI currently shares with its competitors. Sales have been adversely affected by the very mild cough/cold season, and the recent negative publicity relating to some of PFI's major products, including naproxen sodium and pseudoephedrine.

The Company relies very heavily on the support of ICC Industries Inc., its majority shareholder. With the Company's less than satisfactory performance in 2004 and the current deterioration of its business, the level of this support has increased. It is essential that the Company be able to adjust its operations to reduce this dependence on ICC Industries Inc.

The board of directors of PFI is considering all of the options available to enable the Company to successfully conduct its business in the current market environment.

The Company's subsidiary, Konsyl Pharmaceutical, Inc., continues to perform well, with the introduction of a new product, SennaPrompt(TM) (http://www.sennaprompt.com/), during 2004. This is, however, a modest portion of the Company s overall business, and to date, has not had a material effect on the overall results, despite the Company's efforts and long-term goal to develop this branded product.

The Company reported in 2004 that it had received a warning letter from the FDA dated May 5, 2004. The FDA and the Company agreed upon the actions to be taken, which have been ongoing now for several months. On Monday, March 14, 2005, the FDA commenced a follow-up inspection of the plant.

ICC Industries Inc. is the holder of approximately 74.5 million shares (about 87%) of the common stock of PFI. ICC is a global leader in the manufacturing, marketing and trading of chemical, plastic and pharmaceutical products. Founded as a trading enterprise in 1950, ICC has expanded its line of business to include manufacturing and production facilities throughout the United States, Europe, Israel, Russia, China and Turkey. ICC had 2004 sales of approximately $1.5 billion.

This press release may contain forward-looking information and should be read in conjunction with the Company's annual report on Form 10-K and quarterly and periodic reports on Forms 10-Q and 8-K, as filed with the Securities and Exchange Commission.

Pharmaceutical Formulations, Inc.

CONTACT: Dr. James C. Ingram of Pharmaceutical Formulations, Inc.,+1-732-985-7100



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES